Middle East & Africa Antibiotics & Antimycotics Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The antibiotics and antimycotics market in the Middle East and Africa is projected to grow significantly, reaching approximately USD 2,187.95 million by 2031, up from USD 1,756.67 million in 2023, reflecting a compound annual growth rate (CAGR) of 2.8% from 2023 to 2031.

Executive Summary and Market Analysis

The market is divided into key regions: Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East and Africa. Several factors are propelling market growth, including the rising incidence of infectious diseases caused by bacteria and fungi, strategic initiatives by industry players such as new product launches and partnerships, and supportive government policies. Additionally, the geographical expansion of market participants and increasing awareness regarding the appropriate use of antibiotics and antimycotics are expected to further stimulate market growth in the upcoming years.

Market Segmentation Analysis

The Middle East and Africa antibiotics and antimycotics market is categorized based on drug class, indication, route of administration, and distribution channel:

Drug Class: The market includes various drug classes such as penicillin, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, penicillin dominated the market share.
Indication: The market is segmented into skin infections, respiratory infections, urinary tract infections (UTI), septicemia, ear infections, gastrointestinal infections, and others. Respiratory infections held the largest market share in 2023.
Route of Administration: This includes oral, topical, and other methods, with oral administration being the most prevalent in 2023.
Distribution Channel: The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies capturing the largest share in 2023.

Market Outlook

Infectious diseases, caused by various pathogens including bacteria and fungi, pose significant health challenges. According to a 2022 report by ReAct Group, bacterial infections were linked to 77 million deaths globally, excluding tuberculosis, which ranks as the 13th leading cause of death worldwide. The World Health Organization (WHO) reported that tuberculosis (TB) was responsible for 1.3 million deaths in 2022, with a significant number of new cases arising in high-burden countries.

Healthcare-associated infections (HAIs) also contribute to high morbidity and mortality rates, imposing substantial costs on healthcare systems. Common antibiotics prescribed for conditions like hospital-acquired diarrhea and urinary tract infections include metronidazole, vancomycin, ofloxacin, ceftriaxone, and amoxicillin.

Moreover, the rise in fungal infections is a growing concern, with the Global Action Fund for Fungal Infections (GAFFI) estimating that over 80 million people are at high risk of developing fungal diseases annually, leading to approximately 6.55 million cases of life-threatening infections and 3.75 million deaths. Azoles and Amphotericin B are frequently used antimycotics for treating these infections. The increasing prevalence of bacterial and fungal infections underscores the urgent need for effective antibiotics and antimycotics.

Country Insights

The market analysis by country reveals that Saudi Arabia held the largest share in 2023. The growth in Saudi Arabia's antibiotics and antimycotics market is driven by rising healthcare expenditures, a growing prevalence of infectious diseases, and ongoing health initiatives aimed at combating antibiotic resistance. UTIs are notably common, accounting for 10% of all infections in the country, while the prevalence of tuberculosis is reported at 17%, exceeding the global average.

Recent product innovations, such as the launch of STIMULAN by Biocomposites in October 2023, which serves as an antibiotic carrier for wound healing, are expected to enhance market opportunities in Saudi Arabia.

Company Profiles

Key players in the antibiotics and antimycotics market include Pfizer Inc., Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc., GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc., and Astellas Pharma Inc. These companies are pursuing various strategies, including market expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase market share.

Product Code: BMIRE00032107

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Middle East & Africa Antibiotics and Antimycotics Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Infectious Diseases
- 4.1.2 Growing Awareness About Fungal Infections
4.2 Market Restraints
- 4.2.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
4.3 Market Opportunities
- 4.3.1 Ongoing Funding and Research & Development Initiatives
4.4 Future Trends
- 4.4.1 Technological Advancements in Product Development and Treatment Delivery Approaches
4.5 Impact of Drivers and Restraints:

5. Middle East & Africa Antibiotics and Antimycotics Market - Analysis

5.1 Middle East & Africa Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
5.2 Middle East & Africa Antibiotics and Antimycotics Market Forecast Analysis

6. Middle East & Africa Antibiotics and Antimycotics Market Analysis - by Drug Class

6.1 Penicillin
- 6.1.1 Overview
- 6.1.2 Penicillin: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Cephalosporines
- 6.2.1 Overview
- 6.2.2 Cephalosporines: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.3 Carbapenems
- 6.3.1 Overview
- 6.3.2 Carbapenems: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.4 Macrolides
- 6.4.1 Overview
- 6.4.2 Macrolides: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.5 Aminoglycosides
- 6.5.1 Overview
- 6.5.2 Aminoglycosides: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.6 Quinolones
- 6.6.1 Overview
- 6.6.2 Quinolones: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.7 Sulfonamides
- 6.7.1 Overview
- 6.7.2 Sulfonamides: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.8 Tetracyclines
- 6.8.1 Overview
- 6.8.2 Tetracyclines: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.9 Azoles
- 6.9.1 Overview
- 6.9.2 Azoles: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.10 Others
- 6.10.1 Overview
- 6.10.2 Others: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Middle East & Africa Antibiotics and Antimycotics Market Analysis - by Indication

7.1 Skin Infections
- 7.1.1 Overview
- 7.1.2 Skin Infections: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Respiratory Infections
- 7.2.1 Overview
- 7.2.2 Respiratory Infections: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Urinary Tract Infections (UTI)
- 7.3.1 Overview
- 7.3.2 Urinary Tract Infections (UTI): Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Septicemia
- 7.4.1 Overview
- 7.4.2 Septicemia: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Ear Infections
- 7.5.1 Overview
- 7.5.2 Ear Infections: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Gastrointestinal Infections
- 7.6.1 Overview
- 7.6.2 Gastrointestinal Infections: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Middle East & Africa Antibiotics and Antimycotics Market Analysis - by Route of Administration

8.1 Oral
- 8.1.1 Overview
- 8.1.2 Oral: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Topical
- 8.2.1 Overview
- 8.2.2 Topical: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Middle East & Africa Antibiotics and Antimycotics Market Analysis - by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Pharmacies
- 9.3.1 Overview
- 9.3.2 Online Pharmacies: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Middle East & Africa Antibiotics and Antimycotics Market - Country Analysis

10.1 Middle East & Africa
- 10.1.1 Middle East and Africa Antibiotics and Antimycotics Market Overview
- 10.1.2 Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 10.1.2.1 Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 10.1.2.2 Saudi Arabia: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.2.1 Saudi Arabia: Middle East & Africa Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.2.2 Saudi Arabia: Middle East & Africa Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.2.3 Saudi Arabia: Middle East & Africa Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.2.4 Saudi Arabia: Middle East & Africa Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.3 South Africa: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.3.1 South Africa: Middle East & Africa Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.3.2 South Africa: Middle East & Africa Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.3.3 South Africa: Middle East & Africa Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.3.4 South Africa: Middle East & Africa Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.4 United Arab Emirates: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.4.1 United Arab Emirates: Middle East & Africa Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.4.2 United Arab Emirates: Middle East & Africa Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.4.3 United Arab Emirates: Middle East & Africa Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.4.4 United Arab Emirates: Middle East & Africa Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.5 Rest of Middle East & Africa: Middle East & Africa Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.5.1 Rest of Middle East & Africa: Middle East & Africa Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.5.2 Rest of Middle East & Africa: Middle East & Africa Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.5.3 Rest of Middle East & Africa: Middle East & Africa Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.5.4 Rest of Middle East & Africa: Middle East & Africa Antibiotics and Antimycotics Market Share - by Distribution Channel

11. Antibiotics and Antimycotics Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in Antibiotics and Antimycotics Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Pfizer Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Novartis AG
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Sanofi SA
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 F. Hoffmann-La Roche Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Merck & Co Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 GSK Plc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Johnson & Johnson
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Cipla Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Bayer AG
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 AbbVie Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Astellas Pharma Inc
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms